Pulse Biosciences - PLSE Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pulse Biosciences in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" PLSE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PLSE, but not buy additional shares or sell existing shares.
View PLSE analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 1 year target prices for Pulse Biosciences' shares. Their PLSE share price forecasts range from $8.50 to $13.00. On average, they predict the company's share price to reach $11.17 in the next year. This suggests a possible upside of 478.6% from the stock's current price.
View analysts price targets for PLSE or view top-rated stocks among Wall Street analysts.

Pulse Biosciences' stock was trading at $14.81 at the beginning of 2022. Since then, PLSE shares have decreased by 87.0% and is now trading at $1.93.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our PLSE earnings forecast.

Pulse Biosciences, Inc. (NASDAQ:PLSE) announced its quarterly earnings results on Monday, November, 15th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.05. The firm had revenue of $0.57 million for the quarter. Pulse Biosciences had a negative net margin of 2,866.34% and a negative trailing twelve-month return on equity of 290.24%. During the same period in the prior year, the company earned ($0.51) EPS.

2 employees have rated Pulse Biosciences Chief Executive Officer Darrin R. Uecker on Glassdoor.com. Darrin R. Uecker has an approval rating of 100% among the company's employees. This puts Darrin R. Uecker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulse Biosciences investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Bausch Health Companies (BHC), Wayfair (W), Achaogen (AKAO), NVIDIA (NVDA), Portola Pharmaceuticals (PTLA), Enphase Energy (ENPH) and Novavax (NVAX).

(PLSE) raised $20 million in an IPO on Wednesday, May 18th 2016. The company issued 5,000,000 shares at $4.00 per share. MDB Capital Group and Feltl and Company served as the underwriters for the IPO.

Pulse Biosciences trades on the NASDAQ under the ticker symbol "PLSE."

Pulse Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.52%), Westside Investment Management Inc. (0.39%), Griffin Asset Management Inc. (0.23%), Spotlight Asset Group Inc. (0.18%), Ergoteles LLC (0.10%) and Belvedere Trading LLC (0.00%). Insiders that own company stock include Kevin Patrick Danahy, Maky Zanganeh and Mitchell E Levinson.
View institutional ownership trends.

Shares of PLSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PLSE stock can currently be purchased for approximately $1.93.

Pulse Biosciences (NASDAQ:PLSE) has a market capitalization of $71.85 million and generates $1.42 million in revenue each year. The company earns $-63,660,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis.

The company employs 142 workers across the globe.

Pulse Biosciences' mailing address is 3957 POINT EDEN WAY, HAYWARD CA, 94545. The official website for the company is www.pulsebiosciences.com. The company can be reached via phone at (510) 906-4600 or via email at ir@pulsebiosciences.com.